• Chief Executive Officer

    Steven Lydeamore

    Mr Lydeamore is a FCPA, MBA with 29 years' international pharmaceutical experience. He has senior executive experience spanning Asia Pacific, Europe, Latin America and North America in finance, business development, mergers and acquisitions, sales and marketing, manufacturing, and research and development. Mr Lydeamore worked in various finance roles for F.H. Faulding & Co. Limited in Australia over a ten year period followed by four years in the United States at Mayne Pharma (USA) Limited. For the eleven years' prior to joining Bionomics, Mr Lydeamore worked for Apotex Inc., the largest Canadian-owned pharmaceutical company, most recetly as President, Apobiologix. Mr Lydeamore holds a Bachelor of Business (Applied Economics) (Deakin) and a Master of Business Administration (RMIT). He is a Fellow of CPA Australia, Graduate of Australian Institute of Company Directors and Member of Licensing Executives Society Australia & New Zealand.
  • Chief Operating Officer

    Dr Michael West

    Michael joined Anatara Lifesciences as Chief Operating Officer in 2016. He brings to the role a wealth of experience from over 25 years in the pharmaceutical industry internationally. In his career Michael has worked in US based large pharmaceutical companies, Australian Biotechnology companies and as a consultant to Regulatory Authorities as well as public and private pharma-industry companies in Asia-Pacific, the USA and Europe.

    Originally trained as a medicinal chemist, Michael was a member of the team at SmithKline Beecham that led the discovery of HIV drugs in the early 1990’s. His interest in the chemistry of medicines inevitably led to roles in drug development and drug manufacturing. He has applied these skills to the successful development of a generic form of fondaparinux sodium, now marketed globally by Dr Reddy’s Laboratories. A product that is considered one of the most technically challenging drug molecules ever to have reached the market. Michael has also developed new dosage forms for anti-cancer drugs and most recently managed the Chemistry and Manufacture of Anatara’s products.

    As Chief Operating Officer and a qualified Patent & Trademarks Attorney, Michael manages Anatara’s intellectual property portfolio, has primary oversight over Chemistry & Manufacturing, and provides operational leadership on business process within Anatara.